Shaanxi BLOOM Tech Co., Ltd. yog ib qho ntawm cov tuam ntxhab thiab cov muag khoom ntawm carbetocin ntsiav tshuaj hauv Suav teb. Txais tos rau kev lag luam wholesale bulk zoo carbetocin ntsiav tshuaj muag ntawm no los ntawm peb lub hoobkas. Kev pabcuam zoo thiab tus nqi tsim nyog muaj.
Carbetocin ntsiav tshuaj, nthuav tawm cov txiaj ntsig tseem ceeb hauv kev tswj xyuas qhov txuas ntxiv thiab sib xws ntawm cov txheej txheem sib cog lus, thiab nws cov txiaj ntsig tsis yog luv luv - lub sij hawm stimulation, tab sis ruaj khov los ntawm ntau- theem thiab ntau - lub hom phiaj kev cai lom neeg. Txhawm rau kom paub meej nws cov hauv paus ntsiab lus, kev tshuaj xyuas ntawm nws cov txheej txheem tseem ceeb ntawm kev ua haujlwm tuaj yeem ua los ntawm plaub qhov loj: cov qauv molecular thiab receptor binding, cellular signal transduction, pharmacokinetic yam ntxwv hauv vivo, thiab receptor regulatory mechanisms. Cov ntsiab lus tshwj xeeb yog raws li hauv qab no.
Peb Cov KhoomKev piav qhia
|
|
|
Carbetocin COA
Stable Receptor Binding thiab Slow Dissociation ntawm Carbetocin
(I) Optimized Molecular Structure nrog Qhov Zoo Tshaj Plaws Receptor Binding Affinity:
Los ntawm cov phiaj xwm kev hloov kho tshuaj thiab kev ua kom zoo ntawm cov qauv, cov tshuaj ua tiav ntau dua spatial compatibility nrog nws cov hom phiaj sib xws. Nws tuaj yeem tsim kev sib txuas ruaj khov nrog lub hom phiaj ntawm qhov chaw uas muaj zog ruaj khov dua, tsim kom muaj lub hauv paus rau nws ntev - cov nyhuv kav ntev ntawm qib molecular.
Txo txo qis kev sib cais tom qab siv yeeb tshuaj-Txoj kev khi:
Thaum cov tshuaj - lub hom phiaj complex tau tsim, nws cov qauv kev ruaj ntseg yog txhim khu kev qha. Nws tsis raug cuam tshuam los ntawm kev tsis sib haum xeeb lossis hloov pauv sai sai hauv lub sijhawm luv luv, tiv thaiv kev cuam tshuam ntawm nws cov txiaj ntsig tshwm sim los ntawm kev tshem tawm ntxov ntxov ntawm lub hom phiaj.
(II) Lub Hom Phiaj Nyob Ntev Ntev, Tswj Kev Ua Haujlwm Txuas Ntxiv:
Vim nws cov yam ntxwv dissociation qeeb, cov tshuaj tuaj yeem tuav lub hom phiaj khi rau lub sijhawm ntev. Nws tsis tu ncua activates downstream physiological signaling pathways, es tsis poob nws txoj cai tswj lub hom phiaj tom qab tsuas yog ib tug luv luv trigger.
Sustained Signal Transduction Txheej txheem yam tsis muaj kev cuam tshuam sai ntawm Pharmacological teebmeem:
Lub hom phiaj ruaj khov ua kom muaj kev txuas ntxiv ntawm cov teeb liab transduction. Qhov no tso cai rau cov tshuaj tswj cov teebmeem kom tso tawm kom zoo thiab tsis tu ncua, tsis txhob muaj qhov hloov pauv uas tshwm sim los ntawm qhov pib sai thiab sai offset. Yog li ntawd, nws ua tiav - ntev thiab ruaj khov kev tswj xyuas cov txiaj ntsig tshuaj.
Daim ntawv thov tseem ceeb ntawm Carbetocin
(I) Lub Sijhawm Ua Haujlwm ntev dua, tshem tawm qhov xav tau rau kev siv ntau zaus:
Piv nrog rau cov pa luv luv- ua yeeb yam oxytocin, Carbetocin nta cov qauv molecular optimized uas ua rau cov metabolism hauv qeeb qeeb hauv lub cev, cuam tshuam nws lub sijhawm ua haujlwm. Ib qho kev tswj hwm ib zaug tom qab yug me nyuam hauv plab tuaj yeem tswj tau cov kab mob uterine zoo rau lub sijhawm ntev. Qhov no tshem tawm qhov xav tau rau cov kws kho mob kom nquag siv tshuaj ntxiv, txo qhov zaus ntawm kev kho mob thiab txo qhov kev pheej hmoo ntawm kev noj tshuaj tsis tu ncua lossis ncua sijhawm.
(II) Txhim kho kev ruaj ntseg ntawm Uterine Contractions, Aiding Uterine Involution:
Cov teebmeem ntawm tus qauv oxytocin ploj zuj zus sai, uas tuaj yeem ua rau muaj kev hloov pauv hauv kev cog lus muaj zog lossis cuam tshuam hauv cov qauv kev cog lus. Nyob rau hauv sib piv, Carbetocin ua rau lub tsev menyuam du nqaij nyob rau hauv ib tug sustained thiab ruaj khov yam, kom ntseeg tau tas mus li thiab uniform contraction quab yuam. Qhov kev ruaj ntseg no pab tiv thaiv kev ncua ntawm uterine involution los ntawm contraction variability, txhawb lub tsev menyuam rov qab mus rau nws li qub loj thiab ua hauj lwm zoo dua.
(III) Kev kho mob yooj yim dua, txhim kho kev noj qab haus huv zoo:
Los ntawm kev tshem tawm qhov xav tau ntau zaus rov- noj, Carbetocin txo cov haujlwm uas cuam tshuam nrog kev tswj hwm tshuaj rau cov neeg ua haujlwm kho mob. Qhov no tso cai rau lawv muab sijhawm ntau thiab kev saib xyuas rau kev saib xyuas tom qab yug me nyuam rau leej niam. Tsis tas li ntawd, nws cov txiaj ntsig ntev -ntev tuaj yeem txo cov niam txiv tsis xis nyob cuam tshuam nrog kev txhaj tshuaj, ua kom tus neeg mob tau txais kev nplij siab thaum lub sijhawm rov zoo. Yog li, nws sib npaug kev kho mob ua haujlwm nrog kev txhim kho niam txiv.
(IV) Lub Hom Phiaj Muaj Zog nrog Kev Txhim Kho Kev Nyab Xeeb Kev Nyab Xeeb:
Carbetocin ua feem ntau thiab tshwj xeeb ntawm cov leeg nqaij ntawm lub tsev menyuam txhawm rau tswj kev contractions, nrog rau cov teebmeem me me rau lwm lub cev. Piv nrog rau tus qauv oxytocin, qhov kev txiav txim siab no txo qhov muaj peev xwm ua rau tsis xis nyob uas tshwm sim los ntawm qhov tsis muaj - cov teebmeem tshwj xeeb. Los ntawm kev tswj hwm uterine contractions thiab txhawb kev koom tes, qhov kev tsom xam no ntxiv txhim kho qhov kev nyab xeeb ntawm nws daim ntawv thov kev kho mob.
Carbetocin Clinical Application Data
Dosing zaus thiab ntxiv kev cuam tshuam cov ntaub ntawv ntawmcarbetocin ntsiav tshuaj:
- Canadian ob- qhov muag tsis pom kev sim (n=212): Tom qab ib koob tshuaj ib zaug, tus nqi ntawm kev xav tau kev cuam tshuam uterotonic ntxiv tsuas yog 13%, sawv cev rau 59 feem pua ntawm qhov txo qis piv rau cov placebo pab pawg (72%), nrog qhov sib txawv tseem ceeb (p<0.001).
- Indian multi-center study (n=440)): Piv nrog rau cov lus luv luv- ua yeeb yam, Carbetocin txo qhov xav tau rau cov txheej txheem kev tswj hwm tshuaj ntxiv los ntawm 62%, txo qis kev ua haujlwm kho mob.
Hla -Cov ntaub ntawv kho mob hauv cheeb tsam:
- Mev kev tshawb fawb soj ntsuam ntawm carbetocin: Tom qab- kev tswj hwm, qhov tshwm sim ntawm cov ntshav poob qis mus txog 81%, ntau dua li cov pab pawg npaj (55%), p=0.05.
- Chinese multi-center meta-analysis (11 studies, cumulative sample size >2000 tus neeg mob): Kev txhim kho qhov ntsuas qhov ntsuas ntshav tsis txaus hauv 24 teev yog -111.07, 95% CI [-189.34, -32.80], p=0.005.
- Kev tshawb fawb soj ntsuam kev phais mob xwm txheej sab hnub tuaj Asia thaum muaj xwm ceev (n=350): Kev poob ntshav hnyav yog 7.43%, qis dua li pab pawg npaj ua ke (18.86%), p=0.0015.
Physiological Parameter Stability Data:
- Asia-Pacific soj ntsuam cov ntaub ntawv soj ntsuam: Tom qab- kev tswj hwm, qhov nruab nrab hemoglobin poob qis tau txo los ntawm 0.46 g / dL, qhia txog kev saib xyuas zoo dua ntawm cov ntshav ntim homeostasis, p=0.03.
- Cov ntaub ntawv sib sau thoob ntiaj teb qhia tau tias Carbetocin txo qhov kev pheej hmoo ntawm kev xav tau ntshav los ntawm 48% (RR=0.52, 95% CI 0.38–0.72), nrog rau cov pov thawj tseeb me ntsis.
Cov ntaub ntawv kev nyab xeeb
- Ntiaj teb no ntau- chaw saib xyuas kev nyab xeeb (nrog rau Tebchaws Europe, Asia, Americas, thiab Africa): Cov xwm txheej tsis zoo tag nrho tsis pom qhov txawv ntawm qhov sib txawv piv rau cov qauv luv luv - kev npaj ua yeeb yam, nrog kev ua siab ntev.
- European lub koom haum tswj hwm cov ntawv ceeb toom: Tshaj tawm- kev tswj hwm qhov xwm txheej tsis zoo yog<1% , with no region-specific safety risks identified.
Duration ntawm Effect Data:
- Ntiaj teb no multi-center pharmacokinetic kev tshawb fawb qhia tau hais tias tom qab ib tug txhaj tshuaj intravenously, lub sij hawm zoo ntawm qhov kev txiav txim mus txog 8-12 teev, ho ntev dua li cov pa luv luv - ua yeeb yam analogues (uas kav ntev li 3-10 feeb).
- Hla-cov ntaub ntawv tau lees paub los ntawm Tebchaws Europe, North America, thiab Asia tsis tu ncua ua kom pom lub plasma ib nrab- lub neej ntawm kwv yees li 40–50 feeb, muab kev txhawb nqa metabolic ruaj khov rau nws lub sijhawm ntev - ua haujlwm.
Stabilize lub tsev menyuam kom paub meej ntxiv thiab txawm tias quab yuam kev faib tawm
Kom tuav anruam thiab uniform contractile xeev, cov txheej txheem tseem ceeb tuaj yeem piav qhia meej los ntawm peb qhov kev xav: kev siv tshuab lom neeg, kev sib cuam tshuam ntawm molecular, thiab kev tswj hwm metabolic, raws li hauv qab no:
01.Structural modification mediates ruaj khov receptor binding, nteg lub hauv paus rau nruam contractionLos ntawm qhov kev xav ntawm biomolecular mechanisms, carbetocin tau hloov kho cov qauv tshuaj lom neeg nrog kev ua kom zoo ntawm peptide bonds hauv nws cov pob txha molecular. Piv nrog rau cov pa oxytocin, cov pab pawg lipophilic tau koom ua ke rau hauv nws cov qauv molecular, thiab kev teeb tsa ntawm receptor-binding active site yog ua kom zoo dua qub, uas ua rau muaj txiaj ntsig zoo ntawm qhov sib ntxiv ntawm cov tshuaj molecule thiab nws cov receptor sib raug.
Xws li cov qauv kev ua kom zoo ncaj qha txo cov kev sib cais tas li (Ki tus nqi) ntawm cov tshuaj-receptor complex. Cov ntaub ntawv tseem ceeb hauv vitro biological qhia tau hais tias nws cov nqi Ki yog txo los ntawm ntau dua 60% piv nrog cov pa oxytocin, qhia tau zoo heev txhim kho kev ruaj ntseg ntawm cov tsim complex. Lub complex tsis tshua muaj rau kev sib cais ntawm tus kheej, tso cai rau kev ua haujlwm mus sij hawm ntev ntawm receptor-binding qhov chaw thiab muab lub hauv paus molecular rau kev ua kom muaj txiaj ntsig ntawm cov ntawv cog lus. Qhov no tseem ceeb zam kev cuam tshuam ntawm kev cog lus los ntawm kev sib cais ntawm receptor sai thiab ua kom muaj kev txuas ntxiv ntawm cov txheej txheem contractile.
02.Uniform activation of signaling pathways regulates intensity contractile intensityLos ntawm qhov kev xav ntawm cov teeb liab hloov pauv ntawm tes, raws li ib qho tshwj xeeb receptor agonist, carbetocin tuaj yeem ua kom cov G protein-coupled receptor signaling pathways raws li receptor binding, yog li tswj kev ruaj khov ntawm kev faib tawm ntawm intracellular calcium ions (Ca²⁺). Tsis zoo li "kev ua kom nquag plias thiab kev lwj sai" cov qauv qhia ntawm cov pa oxytocin, carbetocin-mediated teeb liab transduction yog yam ntxwv ntawm uniformity thiab persistence.
Tom qab receptor khi, nws maj mam thiab tsis tu ncua txhawb kev nkag mus ntawm extracellular Ca²⁺ thiab inhibits qhov kev tso tawm sai ntawm Ca²⁺ los ntawm cov khw muag khoom intracellular, tswj intracellular Ca²⁺ concentration nyob rau hauv qhov chaw ruaj khov thiab tsim nyog (10⁻⁷–10⁻⁶ mol / L) thiab tiv thaiv kev hloov pauv. Txij li thaum intracellular Ca²⁺ concentration ncaj qha txiav txim siab qhov kev siv thiab kev sib dhos ntawm cov leeg nqaij sib sib zog nqus, ib qho khoom noj khov kho ntawm Ca²⁺ ua rau cov leeg nqaij sib luag los tsim kom muaj kev sib haum xeeb thiab sib koom ua ke. Kev cog lus muaj zog ntau dhau vim yog siab dhau Ca²⁺ lossis tsis muaj zog contraction vim kev poob qis ntawm Ca²⁺ sai, yog li ua tiav kev tswj tau thiab ua kom muaj zog sib xws.
03.Optimized pharmacokinetics kom ntseeg tau tias cov tshuaj muaj txiaj ntsig zoo thiab ruaj khov:
Nyob rau theem ntawm cov tshuaj metabolism, kev hloov pauv molecular ntawm carbetocin tsis tsuas yog txhim kho receptor-binding affinity tab sis kuj tseem hloov pauv nws hauv vivo metabolic zog. Cov tshuaj yog resistant rau degradation los ntawm endogenous peptidases. Nyob rau hauv sib piv rau cov pa oxytocin, uas yog sai hydrolyzed los ntawm plasma oxytocinase nrog ib nrab-lub neej ntawm tsuas yog 3-10 feeb, carbetocin muaj ib tug ntev ib nrab-lub neej ntawm 40-50 feeb thiab ib tug ntau dua 70% txo nyob rau hauv lub systemic clearance tus nqi.
Qhov kev ua kom zoo metabolic no tso cai rau carbetocin los tsim cov ntshav plasma ruaj khov-lub sijhawm nkhaus tom qab kev tswj hwm ib leeg, zam kev hloov pauv ntawm cov tshuaj. Yog li ntawd, kev ua kom cov receptors tseem zoo ib yam thiab txhawb nqa yam tsis muaj kev cuam tshuam sai ntawm kev ua tau zoo, ntxiv kev sib koom ua ke thiab kev sib koom ua ke ntawm kev cog lus.
04.Inhibition ntawm receptor desensitization tiv thaiv txawv txav contractile hloov pauv:Los ntawm kev pom ntawm kev tswj hwm kev noj qab haus huv, carbetocin tuaj yeem tswj hwm kev sib kis tsis tu ncua ntawm kev cog lus los ntawm kev txo qis receptor desensitization. Lub sijhawm ntev lossis nrawm nrawm los ntawm cov pa oxytocin zoo li ua rau cov neeg mob desensitization (piv txwv li, txo qhov kev ua haujlwm rau cov tshuaj), uas tuaj yeem ua rau tsis muaj zog thiab tsis muaj zog atherosclerosis. Hauv qhov sib piv, cov qauv molecular ntawm carbetocin tshwj xeeb inhibits kev ua kom cov proteins koom nrog hauv receptor desensitization thiab txo cov kev hloov pauv ntawm cov phosphorylation ntawm receptors, ua kom cov receptors siab heev rau cov tshuaj.
Thaum lub sij hawm tas mus li kev ua yeeb yam, cov teeb liab hloov pauv tseem tsis tau ploj mus thiab tsis muaj kev cuam tshuam, ntxiv kom muaj kev ruaj khov, tsis muaj kev hloov pauv-dawb contractile lub xeev nrog nruab nrab thiab tsis sib xws. Los ntawm kev zam qhov txawv txav tshwm sim los ntawm receptor desensitization, nws muab kev txhawb nqa kev cog lus ruaj khov rau cov ntaub so ntswg rov qab thiab txhawb nqa kev kho kom zoo dua ntawm kev ua haujlwm ntawm lub cev.
Cim npe nrov: carbetocin ntsiav tshuaj, lwm tus neeg, manufacturers, hoobkas, lag luam wholesale, yuav, nqe, tej, kev muag khoom